Sugi Predict

Sugi Predict / Compounds / SCHEMBL2544516

SCHEMBL2544516

SCHEMBL2544516

C[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTRB1 P17538 3/20 0.57
▸ ACE P12821 3/20 0.57
▸ MME P08473 4/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ HPGD P15428 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ ECE1 P42892 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ NPEPPS P55786 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ CTSS P25774 2/20 0.52
▸ CTSK P43235 1/20 0.52
▸ CTSL P07711 1/20 0.52
▸ CTSB P07858 1/20 0.52
▸ MMP8 P22894 1/20 0.51
▸ OPRD1 P41143 3/20 0.51
▸ OPRM1 P35372 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7588968 1.00 CTRB1 (0.57) CTRB1ACEMMEALDH1A1HPGD
SCHEMBL29569076 0.93 MME (0.54) CTRB1ACEMMECTSBMMP8
SCHEMBL30533128 0.92 NAALAD2 (0.50) CTRB1ACECTSSCTSLCTSB
SCHEMBL29531333 0.89 OPRD1 (0.55) ACEMMECTSSCTSKCTSL
SCHEMBL29591265 0.89 ACE (0.54) ACEMMEALDH1A1HPGDMAPK1
SCHEMBL15328626 0.89 OPRD1 (0.55) ACEMMECTSSCTSKCTSL
SCHEMBL15328632 0.89 OPRD1 (0.55) ACEMMECTSSCTSKCTSL
SCHEMBL18515816 0.89 OPRD1 (0.57) CTRB1ACEMMECTSSCTSL
SCHEMBL11109838 0.88 OPRD1 (0.54) CTRB1KMT2ACTSSCTSKCTSL
SCHEMBL29350735 0.87 OPRD1 (0.58) ACEMMEALDH1A1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116925178-A Active peptide, composition and application thereof in preparation of product with effect of reducing fine lines and/or wrinkles 深圳海创生物科技有限公司 2023-10-24 — — CN claimed
CN-115746103-A Preparation method of Bulevirtide 深圳市健翔生物制药有限公司 2023-03-07 — — CN claimed
CN-115746104-A Preparation method of Bulevirtide 深圳市健翔生物制药有限公司 2023-03-07 — — CN claimed
EP-0142231-B1 PROCESS FOR PRODUCING SEQUENTIAL POLYAMINO ACID RESIN NITTO BOSEKI CO., LTD. (JP) 1987-11-11 — — EP claimed
EP-0142231-A1 Process for producing sequential polyamino acid resin NITTO BOSEKI CO., LTD. (JP) 1985-05-22 — — EP claimed
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 — — US disclosed
CN-116925178-A Active peptide, composition and application thereof in preparation of product with effect of reducing fine lines and/or wrinkles 深圳海创生物科技有限公司 2023-10-24 — — CN disclosed
CN-116925178-A Active peptide, composition and application thereof in preparation of product with effect of reducing fine lines and/or wrinkles 深圳海创生物科技有限公司 2023-10-24 — — CN disclosed
CN-115746103-A Preparation method of Bulevirtide 深圳市健翔生物制药有限公司 2023-03-07 — — CN disclosed
CN-115746104-A Preparation method of Bulevirtide 深圳市健翔生物制药有限公司 2023-03-07 — — CN disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 — — US disclosed
US-20110262962-A1 METHOD FOR PRODUCING PEPTIDES AJINOMOTO CO., INC. (JP) 2011-10-27 — — US disclosed
EP-0884389-A1 Enzyme participating in C-terminal amidation, and method of preparing same and use thereof SHISEIDO COMPANY LIMITED (JP) 1998-12-16 — — EP disclosed
EP-0438600-B1 ENZYMES WHICH PARTICIPATE IN C-TERMINAL AMIDATION, AND PRODUCTION AND USE THEREOF SHISEIDO CO LTD (JP) 1996-02-07 — — EP disclosed
EP-0666318-A1 Enzyme participating in c-terminal amidation, and method of preparing same and use thereof SHISEIDO COMPANY LIMITED (JP) 1995-08-09 — — EP disclosed
US-5354675-A Amidation of glycine SHISEIDO COMPANY LTD. (JP) 1994-10-11 — — US disclosed
EP-0447547-B1 C-TERMINUS AMIDATION ENZYME COMPOSITION, PROCESS FOR ITS PREPARATION AND ITS USE SHISEIDO CO LTD (JP) 1994-07-27 — — EP disclosed
EP-0447547-A1 C-TERMINUS AMIDATION ENZYME COMPOSITION, PROCESS FOR ITS PREPARATION AND ITS USE SHISEIDO COMPANY LIMITED (JP) 1991-09-25 — — EP disclosed
EP-0438600-A1 ENZYMES WHICH PARTICIPATE IN C-TERMINAL AMIDATION, AND PRODUCTION AND USE THEREOF SHISEIDO COMPANY LIMITED (JP) 1991-07-31 — — EP disclosed
US-4438249-A Biodegradable polyurethane urea acyl semicarbazides for the manufacture of biodegradable alloimplants LIPATOVA TATYANA E (SU) 1984-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP CTRB1 3049/4885ACE 1190/4885MME 824/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD CTRB1 326/4885ACE 486/4885MME 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.